A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)
Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease
Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease
Objective: To identify genes involved in the degeneration of the dopaminergic neurons (DN) of the substantia nigra (SN) by inflammation. Background: Parkinson’s disease (PD) is…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Parkinson's disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity…Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model
Objective: The objective of this study was to investigate the gut microbiota in a pilot cohort of Australian patients with PD, and a rodent model…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Huntington’s disease gene expansion carriers (HDGECs) using [11C]BU99008 PET, a novel radioligand with high specificity and…Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease
Objective: We postulate alterations of the intestinal barrier (or leaky guts) enhances inflammation, as well as the production of alpga (α)-synuclein which has characteristic pathological…Serum mucosal chemokine levels in patients with Parkinson disease.
Objective: To investigate the relationship between mucosal chemokines including CXCL14 and CCL28) and impairment in motor/non-motor function among patients with Parkinson’s disease. Background: Parkinson disease…CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease
Objective: Activated microglia and increased cytokine levels could precede neurodegeneration in neuro-inflammation in A53T mice, and CXCL12 was found increased in plasma CNS-derived exosomes, which…The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease
Objective: To investigate whether clinical phenotypes can be predicted by the assessment of gut microbiome and serum inflammatory profile of PD patients. Background: Recent evidence…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 25
- Next Page »